Benedetta Stefanini, Laura Bucci, Valentina Santi, Nicola Reggidori, Lorenzo Lani, Alessandro Granito, Filippo Pelizzaro, Giuseppe Cabibbo, Mariella Di Marco, Giorgia Ghittoni, Claudia Campani, Gianluca Svegliati-Baroni, Francesco Giuseppe Foschi, Edoardo G Giannini, Elisabetta Biasini, Carlo Saitta, Donatella Magalotti, Angelo Sangiovanni, Maria Guarino, Antonio Gasbarrini, Gian Ludovico Rapaccini, Alberto Masotto, Rodolfo Sacco, Gianpaolo Vidili, Andrea Mega, Francesco Azzaroli, Gerardo Nardone, Giovanni Brandi, Simone Sabbioni, Alessandro Vitale, Franco Trevisani
BACKGROUND AND AIMS: The efficacy of systemic therapy for unresectable advanced hepatocellular carcinoma (aHCC) has not been proven in patients with Child-Pugh (C-P) B cirrhosis. Nevertheless, in real-world these patients are treated both with tyrosine kinase inhibitors (TKIs) and with metronomic capecitabine (MC). This study aimed to compare sorafenib and MC outcomes versus best supportive care (BSC) in C-P B patients. METHOD: Between 2008 and 2020, among 774 C-P B patients with aHCC not amenable/responsive to locoregional treatments, 410 underwent sorafenib, 62 MC, and 302 BSC...
February 9, 2024: Digestive and Liver Disease